Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $289
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and raised the price target from $264 to $289.
September 17, 2024 | 3:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has reaffirmed its positive outlook on Ascendis Pharma by maintaining an Overweight rating and increasing the price target to $289, indicating confidence in the company's future performance.
The increase in the price target from $264 to $289 by a major financial institution like Wells Fargo suggests a positive outlook on Ascendis Pharma's future performance. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100